

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Gilfillan, C;Naidu, P;Gunawan, F;Hassan, F;Tian, P;Elwood, N

Title:

Leukocyte telomere length in the neonatal offspring of mothers with gestational and pre-gestational diabetes

Date:

2016-10-01

Citation:

Gilfillan, C., Naidu, P., Gunawan, F., Hassan, F., Tian, P. & Elwood, N. (2016). Leukocyte telomere length in the neonatal offspring of mothers with gestational and pre-gestational diabetes. Plos One, 11 (10), <https://doi.org/10.1371/journal.pone.0163824>.

Persistent Link:

<https://hdl.handle.net/11343/257351>

License:

CC BY

RESEARCH ARTICLE

Leukocyte Telomere Length in the Neonatal Offspring of Mothers with Gestational and Pre-Gestational Diabetes

Christopher Gilfillan^{1*}, Pratyusha Naidu¹, Florence Gunawan¹, Fadwa Hassan², Pei Tian³, Ngaire Elwood³

1 Eastern Health Clinical School, Monash University, Box Hill, Victoria, Australia, **2** Peninsula Health, Frankston, Victoria, Australia, **3** Cord Blood Stem Cell Research, Murdoch Children's Research Institute, Parkville, Victoria, Australia

* chris.gilfillan@easternhealth.org.au



OPEN ACCESS

Citation: Gilfillan C, Naidu P, Gunawan F, Hassan F, Tian P, Elwood N (2016) Leukocyte Telomere Length in the Neonatal Offspring of Mothers with Gestational and Pre-Gestational Diabetes. PLoS ONE 11(10): e0163824. doi:10.1371/journal.pone.0163824

Editor: Gabriele Saretzki, University of Newcastle, UNITED KINGDOM

Received: July 25, 2016

Accepted: September 14, 2016

Published: October 13, 2016

Copyright: © 2016 Gilfillan et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All data is presented in the paper as group data. Individual level data is supplied as a supplementary document. The data is de-identified and identified data cannot be released under the terms of the consent document.

Funding: This project was funded by internal funds arising from private practice billings of the principle investigator held within the organization (Peninsula Health) for the purposes of education and research. This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Abstract

Aims

Telomeres undergo shortening with cell division, accelerated by increased oxidative stress. We aimed to demonstrate shortened telomeres in the offspring of mothers who have diabetes as a consequence of exposure to increased oxidative stress during intrauterine development.

Methods

We examined the level of glycaemia (glucose, HbA1c, fructosamine), oxidative stress (lipid peroxidation) and the levels of antioxidant enzymes (Superoxide dismutase (SOD) and Selenium dependent glutathione peroxidase) and correlate these findings with mean telomere length (TL) in maternal and foetal blood in groups of pregnant women with pre-gestational diabetes (PGD), gestational diabetes (GD) and a euglycaemic control group.

Results

Foetal and maternal glucose, maternal HbA1c, and foetal insulin and C-peptide were higher in the PGD group with the GD group being intermediate. Markers of oxidative stress did not vary between groups with the exception of foetal SOD activity that was highest in the GD group. There were no detectable differences in maternal or foetal TL between study groups. An exploratory analysis looking at correlations between glycaemic and oxidative stress parameters and TL revealed a negative correlation between maternal and foetal glucose and TL across the whole study population. This relationship held for the short-term marker of glycaemic control, fructosamine.

Conclusions

We were unable to show significant telomere shortening in the offspring of mothers with PGD or GD. Exploratory analysis revealed a relationship between foetal TL and short-term

Competing Interests: The authors have declared that no competing interests exist.

glycaemia particularly in PGD. It is possible that increased telomerase activity can compensate for long-term increased oxidative stress but not for short-term dysglycaemia.

Introduction

The view that an adverse intrauterine environment during pregnancy contributes to poor long-term health in the offspring is well established. There is some evidence that the offspring of women with pre-gestational type 1 diabetes, the archetypal adverse intrauterine environment, are at risk of developing glucose intolerance and cardiovascular disease in young childhood and adolescence [1].

Telomeres are nucleoprotein structures, located at the ends of chromosomes and are subject to shortening at each cycle of cell division. Telomeres consist of stretches of repetitive DNA with a high G-C content and are reported to be highly sensitive to damage induced by oxidative stress.[2] Telomere length shortens progressively during each round of cell division, accelerated by inflammation and oxidative stress, to a critical length, called the Hayflick limit, beyond which replicative senescence will be triggered. A number of associated proteins participate in the control of telomere length and include TRF1, TRF2, Ku86 and the enzyme telomerase. Telomerase itself consists of two components: the catalytic protein, a reverse transcriptase, (TERT), and the RNA template, (Terc)[3].

In humans, telomere length declines significantly with age and shorter leucocyte telomere length has been associated with T2DM [4] and its related condition such as obesity [5], insulin resistance [6], IGT [7] and atherosclerosis [8]. Despite these associations it remains unclear whether telomere shortening is a cause or a consequence of diabetes. Two recent studies have helped to clarify this. One study found that a shortened telomere length predicted the onset of diabetes in a high risk population independent of other risk factors [9] and in another prospective study revealed an adjusted Hazard Ratio of 2.00 for diabetes comparing the shortest versus the longest telomere length [10].

It is of interest to know whether the offspring of mothers who have diabetes (type 1, 2 or gestational diabetes) have shortened telomeres at birth as a consequence of exposure to increased oxidative stress during the many replicative cycles during embryogenesis in utero. A reduced telomere length in peripheral white blood cells has been associated with the presence of atherosclerosis in adults and if present in offspring of mothers with diabetes it could be another mechanism by which such offspring may carry an increased burden of disease in later life.

T2DM has been shown to be associated with elevated levels of oxidative DNA damage and decreased efficacy of DNA repair [11]. The extent of oxidative stress in mothers with diabetes and their offspring can be measured by the extent of lipid peroxidation and the activity of anti-oxidant enzymes. Assessment of malondialdehyde (MDA) has been used as the marker of lipid peroxidation. Among the different analytical methods established, the reaction with TBA (2-thiobarbituric acid) is the most widely used [12]. Diabetes is associated with increased oxidative stress and the level of TBARs in peripheral blood is elevated in diabetes [13]. TBARs are also elevated in mothers with diabetes and in the cord blood of their offspring [14]. Anti-oxidant enzyme activities (Glutathione-S-transferase (GST), selenium-dependent glutathione peroxidase (Se-GPx), catalase (CAT), and superoxide dismutase (SOD), and glutathione) also reflect oxidative stress [14].

In this study we will examine the level of glycemia (HbA1c, fructosamine), oxidative stress (lipid peroxidation by thiobarbituric acid reactive substances (TBARs)) and the levels of

antioxidant enzymes (Superoxide dismutase (SOD) and Selenium dependent glutathione peroxidase (Se-GPx)) and correlate these findings with telomere length in peripheral blood leukocytes in maternal and foetal (cord) blood in groups of pregnant women with pre-gestational diabetes ($n = 14$, Type 1 $n = 7$, type 2 $n = 7$), gestational diabetes ($n = 20$) and a euglycaemic control group ($n = 18$). Our primary outcome measure, pre-specified, was a difference in mean telomere length between sub-groups by analysis of variance.

Methods

Recruitment and study population

The protocol was approved by the Peninsula Health Human Research and Ethics committee. All recruited patients were consented using approved patient information and consent forms and signed forms were co-signed by the investigator and kept in the patient's file. Women were recruited from the population of women with gestational diabetes and pre-gestational (type 1 and type 2) diabetes attending a diabetes-in-pregnancy clinic at a single centre. Normal women were recruited from the antenatal clinic at the same hospital. Women with diabetes were managed according to the guidelines of the Australia Diabetes in Pregnancy Society. Gestational diabetes was diagnosed on the basis of a 50g glucose challenge test at 26 weeks and if positive (1 hour blood sugar level greater than 8.0mmol/L) a follow up 75 g glucose tolerance test was performed at 28 weeks. Gestational diabetes was diagnosed if the fasting blood glucose was greater than 5.4 mmol/L or the 2-hour value exceeded 8.0 mmol/L. If the capillary glucose levels exceeded 5.4 mmol/L fasting or 7.0mmol/L post-prandially despite adherence to the dietary and exercise prescription insulin therapy was commenced and adjusted to achieve those thresholds. The dietary prescription involved the use of low glycaemic index carbohydrates spread evenly through the day and restriction of dietary fat. Patients were encouraged to remain physically active but no formal exercise program was offered. For obese patients a goal of weight maintenance during pregnancy was established. For those that required insulin a variety of regimens was used from once daily basal insulin to four times daily basal-bolus regimens to insulin pump devices.

Sample handling

Maternal peripheral blood and cord blood were collected at the time of delivery in heparinized tubes. Aliquots were taken for HbA1c, fructosamine, glucose, c-peptide and insulin determinations. After centrifugation buffy coat and plasma were removed and stored at -80°C for assays of telomere length and TBARS respectively. Red cells were washed with normal saline and then lysed in chilled distilled water; the lysate is diluted in phosphate buffer and stored at -80°C for assay of enzyme activities.

The measurement of oxidative stress in maternal and cord blood

Malondialdehyde (MDA) is a naturally occurring product of lipid peroxidation. Lipid peroxidation is a well-established mechanism of cellular injury in both plants and animals and is used as an indicator of oxidative stress in cells and tissues. Lipid peroxides derived from polyunsaturated fatty acids are unstable and decompose to form a complex series of compounds, which include MDA.

The measurement of Thiobarbituric Acid Reactive Substances (TBARS) is a method for screening and monitoring lipid peroxidation. We used Cayman's TBARS assay kit (Cat no 10009055) to assay lipid peroxidation in plasma samples. The MDA-TBA adducts formed by the reaction of MDA and TBA under high temperature (90 – 100°C) and acidic conditions is

measured colorimetrically at 530–540nm. Typically normal human serum or plasma has a lipid peroxide level (expressed in terms of MDA) of 1.86–3.94 μ M.

Superoxide dismutase (SOD) is an enzyme that catalyses the dismutation of the toxic superoxide radical to hydrogen peroxide and oxygen. We measure SOD activity using a commercial kit (Ransod cat no SD 125, Randox Laboratories, UK). Briefly this assay uses the reaction of xanthine with xanthine oxidase to produce superoxide radicals which in turn react to form a red formazan dye. The degree of inhibition of this reaction correlates with the SOD activity in the sample under assay conditions.

Selenium-dependent glutathione peroxidase (Se-GPX) activity is measured by the method of Paglia and Valentine using a commercial kit (Ransel Cat No RS 504 Randox laboratories, UK). Glutathione Peroxidase catalyses the oxidation of Glutathione by Cumene Hydroperoxide. In the presence of Glutathione Reductase and NADPH the oxidised Glutathione is immediately converted to the reduced form with a concomitant oxidation of NADPH to NADP⁺. The decrease in absorbance at 340 nm is measured.

Measurement of telomere length

Genomic DNA isolation and dilution. Genomic DNA (gDNA) was extracted using Gen-Elute™ Mammalian Genomic DNA Miniprep Kit (Sigma, Cat G1N70) according to the instructions of manufacturer for whole blood preparation. The concentration and quality of the gDNA obtained was determined by NanoDrop spectrophotometer (Biolabs) and agarose gel electrophoresis. The gDNA samples were diluted in 1xTE buffer (10mM Tris-HCl, 1mM EDTA, pH 8.0) to a final concentration of 4 ng/ μ l.

Absolute quantitative real-time PCR assay. Average telomere length was measured from gDNA by using a quantitative real-time PCR (qRT-PCR) method previously described [15] with the following modifications.

A standard curve was generated by performing serial dilutions 1 in 3 (6 dilutions). 1Kb plus DNA ladder (Invitrogen Cat. No. 10787–018) was added to each standard dilution to maintain a constant final concentration of DNA of 4ng/ μ l.

Instead of setting up separate oligomer standard curves for TTAGGG repeats and 36B4 (the control for genome copy number), to reduce PCR variation between each run, a standard curve was established by mixing TTAGGG repeats (PT9S) and 36B4 (PT8S) oligonucleotides at dilutions to ensure that test DNA cycle threshold values were within the linear range of the two standard curves.

To reduce the variation introduced by pipetting, the pair of forward and reverse primers were mixed together, aliquoted into an appropriate volume for each run and then stored at -20°C.

All PCR reactions were prepared using QIagility (Qiagen) and reactions were run on a RotorGene 6000 (Corbett). Each sample was analysed in triplicate. Thermal cyclers reaction conditions were set at 50°C for 2 min, 95°C for 5 min followed 30 cycles of 95°C for 15 s, 56°C for 60 s (data was acquired from the Green channel at this step), ending with a melt step. Reactions were set up for 36B4 in the same way as that for the telomere primers except only 150 nM per reaction for forward primer (5' CAGCAAGTGGGAAGGTGTAATCC 3') and reverse primer (5' CCCATTCTATCATCAA CGGGTACAA 3') was used; reaction conditions were set at 50°C for 2 min, 95°C for 5 min followed 35 cycles of 95°C for 15 s, 60°C for 60 s (data was acquired from the Green channel at this step), ending with a melt step.

Real-time PCR data was analysed using the Rotor-Gene 6000 software. The calculated amount of template was exported into MS Excel where the final telomere length was determined according to O'Callaghan, N [15]

Terminal restriction fragments (TRF) assay. Standard TRF assay was performed to verify telomere length obtained using absolute qRT-PCR telomere method. TRF Assay was performed using TeloTAGGG Telomere Length Assay (Roche Cat 12 209 136 001) according to the instructions of manufacturer.

Statistical methods

The effect of diabetes category was assessed for each parameter using analysis of variance and where the parameter was not normally distributed the Kruskal-Wallis comparison of medians was used. Where appropriate, Student's t-test was used to compare individual categories. Relationships between glycaemic parameters and measurements of oxidative stress with foetal telomere length were explored using Pearson's correlation co-efficient.

Results

There were a total of 52 subjects with singleton pregnancies resulting in 52 live births. Twenty subjects had gestational diabetes. 14 patients had pre-gestational diabetes 7 of these were type 1 and the remainder had type 2 diabetes. The mean maternal BMI was in the obese range but there were no statistical differences between groups (Table 1). Application of treatment guidelines (see above) resulted in all pre-gestational subjects with diabetes and 18 of the 20 gestational diabetes patients being treated with insulin. In the gestational diabetes subjects insulin doses ranged from 4 to 52 units daily.

Foetal and Maternal Glycaemic parameters

The average maternal HbA1c was 5.63% (38mmol/mol) with a significant trend to a higher HbA1c in the pre-gestational diabetes group, where the value reached the diabetic range ($>6.0\%$ (42 mmol/mol)). The HbA1c was well-controlled during pregnancy in both groups with diabetes. Plasma glucose at the time of delivery was higher in the group with pre-gestational diabetes ($p<0.01$) and this was reflected in higher cord blood glucose in offspring ($p<0.01$). Foetal insulin levels were also higher in the pre-gestational diabetes group. Although the ANOVAs showed a significant effect of diabetes category this was driven by the pre-gestational group with the gestational diabetes group not differing from controls with respect to any of these parameters. Foetal C-peptide reflected the changes in foetal insulin (Table 2). Maternal and foetal fructosamine was not different between groups (data not shown) and interpretation of maternal insulin and C-peptide levels were compromised by the presence of subjects with type 1 diabetes in the pre-gestational diabetes group (data not shown).

Markers of oxidative stress and Telomere length

Although there was a trend to higher TBARS in mothers and offspring with pre-gestational diabetes, there were no statistical differences between TBARS measurements in maternal or

Table 1. Maternal and foetal characteristics in women with Gestational Diabetes, Pre-gestational Diabetes and controls.

	ALL	Control	GDM	PGDM	ANOVA
Number	52	18	20	14	
Maternal BMI (kg/m ²)	29.4 ± 8.9	28.2 ± 7.1	30.4 ± 10.4	29.5 ± 7.1	NS
Insulin use (percent, mean dose (U))			90%, 13.5	100%, 13.5	NS
Male: Female offspring	25:27	8:10	12:8	5:9	NS
Birthweight (g)	3854 ± 74	3829 ± 116	3864 ± 6	3880 ± 4	NS

doi:10.1371/journal.pone.0163824.t001

Table 2. Glycaemic parameters in maternal plasma and foetal (umbilical cord) plasma at birth in control and diabetic women.

	ALL	Control	GDM	PGDM	ANOVA
Number	52	18	20	14	
Maternal HbA1c % (mmol/mol)	5.6 ± 0.7 (38 ± 5)	5.4 ± 0.3 (36 ± 2)	5.6 ± 0.6 (38 ± 5)	6.1 ± 0.9 (43 ± 6)	p<0.01
Maternal Glucose (mmol/L)	6.7 ± 3.6	5.6 ± 1.2	5.8 ± 2.0	9.4 ± 5.8	p<0.01
Foetal Glucose (mmol/L)	4.6 ± 1.7	3.8 ± 1.0	4.5 ± 1.4	5.6 ± 2.4	p<0.01
Foetal Insulin (mU/L)	7.0 ± 11.8	2.4 ± 3.2	4.2 ± 6.0	17.1 ± 18.3	p<0.005*
Foetal C-Peptide (nmol/L)	0.38 ± 0.28	0.27 ± 0.12	0.36 ± 0.20	0.53 ± 0.44	p<0.05*

*Not normally distributed so analysed by Kruskal-Wallis comparison of medians.

doi:10.1371/journal.pone.0163824.t002

foetal plasma in any group (Table 3). The anti-oxidant enzyme activities showed a trend to be higher in the GDM group in both foetal and maternal plasma. This reached significance for foetal SOD where levels in offspring of women with gestational diabetes were higher than both control and mothers with pre-gestational diabetes ($p<0.05$). Telomere length was significantly longer in foetal compared to maternal peripheral white blood cells. There was no difference in telomere length between groups in either maternal or foetal peripheral white blood cells (Table 3). Thus the primary endpoint was not met.

Relationships between glycaemic parameters oxidative stress and foetal telomere length

An exploratory analysis of the relationships between foetal telomere length and indicators of glycaemic control and oxidative stress within the categories of diabetes within the study was performed. There was a negative correlation between maternal glucose and foetal glucose with foetal telomere length across the whole study population (Fig 1). Further analysis showed that this was due to a striking relationship between maternal glucose and foetal telomere length in the subjects with pre-gestational diabetes, with higher glucose leading to shorter telomere length ($p<0.001$). This relationship held for the short-term marker of glycaemic control, fructosamine, but not for the longer-term marker haemoglobin A1c. Within this group (pre-gestational diabetes), higher maternal glucose was associated with higher maternal TBARS, which in turn predicted a smaller telomere length ($p<0.001$). Even in this sub-group analysis there were no relationship between glycaemic parameters, foetal or maternal telomere length with the anti-oxidant enzyme activities, SOD and Se-GPx.

The relationship of acute glycaemia and foetal telomere length did not reach significance in the gestational diabetes group or the control group, nor did separate examination of those gestational diabetes patients who used insulin increase the strength of the relationship.

Table 3. Foetal and maternal markers of oxidative stress and telomere length in gestational and pre-gestational diabetic pregnancies and controls.

	ALL	Control	GDM	PGDM	ANOVA
Maternal TBARS (μM)	23 ± 10	22 ± 10	22 ± 8	28 ± 12	NS
Foetal TBARS (μM)	24 ± 10	22 ± 8	25 ± 11	27 ± 12	NS
Maternal SOD	288 ± 99	258 ± 53	333 ± 136	264 ± 60	NS
Foetal SOD	298 ± 105	262 ± 64	346 ± 133	270 ± 73	p < 0.05
Maternal Se-GPx	6271 ± 1990	6069 ± 1169	6579 ± 2542	6057 ± 1812	NS
Foetal Se-GPx	4226 ± 1387	4085 ± 1128	4511 ± 1843	4043 ± 997	NS
Maternal telomere length (kb)	7.2 ± 1.3	7.0 ± 1.3	7.2 ± 1.4	7.5 ± 1.2	NS
Foetal telomere length (kb)	10.6 ± 1.9	10.4 ± 1.6	10.9 ± 1.6	10.7 ± 2.4	NS

doi:10.1371/journal.pone.0163824.t003




Fig 1. The relationship between maternal and foetal glucose at delivery (mmol/L) and foetal telomere length (kb).

doi:10.1371/journal.pone.0163824.g001

Discussion

Our primary analysis was unable to show significant telomere shortening in the offspring of mothers with pre-gestational or gestational diabetes. This is consistent with finding of Cross *et al.* who were unable to find telomere shortening in the young adult offspring of mothers with diabetes [16]. However, a recent study did show a significant shortening in telomere length of foetal leucocytes in offspring of mothers with GDM compared to normal pregnancy [17]. Cross *et al.* were also unable to find a relationship between maternal diabetes and cord blood telomere length although they did find increase telomerase activity in cord blood from gestational and type one mothers with diabetes [18]. This can be interpreted as a response to the added stress on telomeres in these offspring. Other authors have found telomere shortening in obese children [19] and in offspring of mothers exposed to neuropsychological stress during pregnancy [20]. Telomere shortening has been observed in trophoblast from placental tissue of mothers with poorly controlled diabetes but not in cord blood leukocytes in the same study [21].

It should be noted that our patients were very well controlled and aggressively treated with insulin. This may have limited our ability to see differences between groups. Insulin therapy will lead to only small differences in glycaemic parameters and will ameliorate the oxidative environment. Telomerase activity may be induced by insulin [22] also limiting our ability to discern differences in telomere length between groups.

Many studies have demonstrated that telomere length is an inheritable trait [23] with both maternal and paternal contributions [24]. There is also a contribution from paternal age [25]. We do not have information on paternity of our offspring. Foetal and maternal telomere lengths were not correlated in our study but we cannot exclude genetic influences on foetal telomere length as confounding factors.

What we have shown in a secondary exploratory analysis is that foetal hyperglycemia (and hyperinsulinemia) found at delivery, particularly in our population with pre-gestational diabetes, was associated with elevated markers of lipid peroxidation and shortened telomeres. This relationship also held with the short-term marker of glycaemic control, fructosamine. Fructosamine is the name given to glycated lysines within serum proteins that have a reducing capacity that can be detected in a colorimetric reaction [26]. The principle serum protein is albumin and as albumin has a half-life of 14 days the measured fructosamine reflects glycaemic control

over that time. In pregnancy fructosamine falls because of changing albumin dynamics and dilution anemia and these factors may contribute to differences across our study groups. Nevertheless our findings suggest that glycemia with the past fortnight may be a relevant determinant of foetal telomere length. It is possible that this relationship reveals oxidative stress acting to shorten telomeres in the medium term with the action of induced telomerase activity repairing this damage over a longer time frame. Telomere length is a dynamic parameter that is capable of short-term change [27] and this may be why we can only find relationships with short-term markers of glycaemic control, while longer-term perturbations are corrected by increased telomerase activity which in turn may be promoted by the action of insulin at least in rats [28]. We have not measure telomerase activity in the current study and so cannot confirm the observation of Cross *et. al.* [18] that telomerase activity is elevated in offspring of mothers with diabetes.

Although telomere shortening may be a consequence of increased oxidative stress in patients with diabetes, there is emerging evidence that telomere shortening may predispose individuals to type 2 diabetes with genetic polymorphisms in telomere pathway genes linked to an increased incidence of type 2 diabetes [29]. Shortened telomeres have also been linked to increased beta-cell senescence and failure [30]. Shortened telomeres are also a feature of diabetic complications, particularly atherosclerosis. Prospective studies have now shown that leukocyte telomere length is independently associated with the risk of incident diabetes in both high-risk and moderate-risk populations [9, 10]. Although we were unable to demonstrate a reduction in telomere length in the offspring of mothers with diabetes we were able to show some evidence of glucose-related telomere shortening and this may still be a mechanism whereby the intra-uterine environment predisposes such offspring to diabetes and atherosclerotic disease later in life.

Alternatively, the currently available evidence suggests that glucose-related telomere shortening at birth is a transient phenomenon and does not persist into adult life and may not have a lasting influence on the risk of type 2 diabetes and metabolic complications in offspring.

Supporting Information

S1 Table. Individual patient data for all participants and their offspring.
(XLSX)

Author Contributions

Conceptualization: CG.

Data curation: CG PN FG FH PT NE.

Formal analysis: CG PN FG.

Funding acquisition: CG.

Investigation: CG FH PT NE.

Methodology: CG.

Project administration: CG.

Resources: CG.

Supervision: CG.

Visualization: CG PN FG.

Writing – original draft: CG.

Writing – review & editing: CG PN FG.

References

1. Leach L, Mann GE. Consequences of fetal programming for cardiovascular disease in adulthood. *Microcirculation*. 2011; 18(4):253–5. doi: [10.1111/j.1549-8719.2011.00097.x](https://doi.org/10.1111/j.1549-8719.2011.00097.x). PMID: [21418386](https://pubmed.ncbi.nlm.nih.gov/21418386/).
2. Houben JM, Moonen HJ, van Schooten FJ, Hageman GJ. Telomere length assessment: biomarker of chronic oxidative stress? *Free radical biology & medicine*. 2008; 44(3):235–46. doi: [10.1016/j.freeradbiomed.2007.10.001](https://doi.org/10.1016/j.freeradbiomed.2007.10.001). PMID: [18021748](https://pubmed.ncbi.nlm.nih.gov/18021748/).
3. Zhu H, Belcher M, van der Harst P. Healthy aging and disease: role for telomere biology? *Clin Sci (Lond)*. 2011; 120(10):427–40. Epub 2011/01/29. doi: [10.1042/CS20100385](https://doi.org/10.1042/CS20100385). PMID: [21271986](https://pubmed.ncbi.nlm.nih.gov/21271986/); PubMed Central PMCID: [PMC3035527](https://pubmed.ncbi.nlm.nih.gov/pmc/articles/PMC3035527/).
4. Zee RY, Castonguay AJ, Barton NS, Germer S, Martin M. Mean leukocyte telomere length shortening and type 2 diabetes mellitus: a case-control study. *Transl Res*. 2010; 155(4):166–9. doi: [10.1016/j.trsl.2009.09.012](https://doi.org/10.1016/j.trsl.2009.09.012). PMID: [20303464](https://pubmed.ncbi.nlm.nih.gov/20303464/).
5. Moreno-Navarrete JM, Ortega F, Sabater M, Ricart W, Fernandez-Real JM. Telomere length of subcutaneous adipose tissue cells is shorter in obese and formerly obese subjects. *International journal of obesity*. 2010; 34(8):1345–8. doi: [10.1038/ijo.2010.49](https://doi.org/10.1038/ijo.2010.49). PMID: [20231841](https://pubmed.ncbi.nlm.nih.gov/20231841/).
6. Gardner JP, Li S, Srinivasan SR, Chen W, Kimura M, Lu X, et al. Rise in insulin resistance is associated with escalated telomere attrition. *Circulation*. 2005; 111(17):2171–7. doi: [10.1161/01.CIR.0000163550.70487.0B](https://doi.org/10.1161/01.CIR.0000163550.70487.0B). PMID: [15851602](https://pubmed.ncbi.nlm.nih.gov/15851602/).
7. Adaikalakoteswari A, Balasubramanyam M, Ravikumar R, Deepa R, Mohan V. Association of telomere shortening with impaired glucose tolerance and diabetic macroangiopathy. *Atherosclerosis*. 2007; 195(1):83–9. doi: [10.1016/j.atherosclerosis.2006.12.003](https://doi.org/10.1016/j.atherosclerosis.2006.12.003). PMID: [17222848](https://pubmed.ncbi.nlm.nih.gov/17222848/).
8. Salpea KD, Humphries SE. Telomere length in atherosclerosis and diabetes. *Atherosclerosis*. 2010; 209(1):35–8. doi: [10.1016/j.atherosclerosis.2009.12.021](https://doi.org/10.1016/j.atherosclerosis.2009.12.021). PMID: [20080237](https://pubmed.ncbi.nlm.nih.gov/20080237/); PubMed Central PMCID: [PMC2862289](https://pubmed.ncbi.nlm.nih.gov/pmc/articles/PMC2862289/).
9. Zhao J, Zhu Y, Lin J, Matsuguchi T, Blackburn E, Zhang Y, et al. Short leukocyte telomere length predicts risk of diabetes in american indians: the strong heart family study. *Diabetes*. 2014; 63(1):354–62. doi: [10.2337/db13-0744](https://doi.org/10.2337/db13-0744). PMID: [23949319](https://pubmed.ncbi.nlm.nih.gov/23949319/); PubMed Central PMCID: [PMC3868043](https://pubmed.ncbi.nlm.nih.gov/pmc/articles/PMC3868043/).
10. Willeit P, Raschenberger J, Heydon EE, Tsimikas S, Haun M, Mayr A, et al. Leucocyte telomere length and risk of type 2 diabetes mellitus: new prospective cohort study and literature-based meta-analysis. *PloS one*. 2014; 9(11):e112483. doi: [10.1371/journal.pone.0112483](https://doi.org/10.1371/journal.pone.0112483). PMID: [25390655](https://pubmed.ncbi.nlm.nih.gov/25390655/); PubMed Central PMCID: [PMC4229188](https://pubmed.ncbi.nlm.nih.gov/pmc/articles/PMC4229188/).
11. Ma D, Zhu W, Hu S, Yu X, Yang Y. Association between oxidative stress and telomere length in Type 1 and Type 2 diabetic patients. *Journal of endocrinological investigation*. 2013; 36(11):1032–7. doi: [10.3275/9036](https://doi.org/10.3275/9036). PMID: [23873360](https://pubmed.ncbi.nlm.nih.gov/23873360/).
12. Jentzsch AM, Bachmann H, Furst P, Biesalski HK. Improved analysis of malondialdehyde in human body fluids. *Free radical biology & medicine*. 1996; 20(2):251–6. Epub 1996/01/01. PMID: [8746446](https://pubmed.ncbi.nlm.nih.gov/8746446/).
13. Yilmaz G, Yilmaz FM, Aral Y, Yucel D. Levels of serum sialic acid and thiobarbituric acid reactive substances in subjects with impaired glucose tolerance and type 2 diabetes mellitus. *Journal of clinical laboratory analysis*. 2007; 21(5):260–4. Epub 2007/09/12. doi: [10.1002/jcla.20181](https://doi.org/10.1002/jcla.20181). PMID: [17847112](https://pubmed.ncbi.nlm.nih.gov/17847112/).
14. Orhan H, Onderoglu L, Yucel A, Sahin G. Circulating biomarkers of oxidative stress in complicated pregnancies. *Archives of gynecology and obstetrics*. 2003; 267(4):189–95. Epub 2003/02/20. doi: [10.1007/s00404-002-0319-2](https://doi.org/10.1007/s00404-002-0319-2). PMID: [12592416](https://pubmed.ncbi.nlm.nih.gov/12592416/).
15. O'Callaghan N, Dhillon V, Thomas P, Fenech M. A quantitative real-time PCR method for absolute telomere length. *Biotechniques*. 2008; 44(6):807–9. Epub 2008/05/15. doi: [000112761](https://doi.org/10.1007/s00112761) [pii] doi: [10.2144/000112761](https://doi.org/10.2144/000112761) PMID: [18476834](https://pubmed.ncbi.nlm.nih.gov/18476834/).
16. Cross JA, Brennan C, Gray T, Temple RC, Dozio N, Hughes JC, et al. Absence of telomere shortening and oxidative DNA damage in the young adult offspring of women with pre-gestational type 1 diabetes. *Diabetologia*. 2009; 52(2):226–34. doi: [10.1007/s00125-008-1207-5](https://doi.org/10.1007/s00125-008-1207-5). PMID: [19034420](https://pubmed.ncbi.nlm.nih.gov/19034420/).
17. Xu J, Ye J, Wu Y, Zhang H, Luo Q, Han C, et al. Reduced fetal telomere length in gestational diabetes. *PloS one*. 2014; 9(1):e86161. doi: [10.1371/journal.pone.0086161](https://doi.org/10.1371/journal.pone.0086161). PMID: [24465936](https://pubmed.ncbi.nlm.nih.gov/24465936/); PubMed Central PMCID: [PMC3899117](https://pubmed.ncbi.nlm.nih.gov/pmc/articles/PMC3899117/).
18. Cross JA, Temple RC, Hughes JC, Dozio NC, Brennan C, Stanley K, et al. Cord blood telomere length, telomerase activity and inflammatory markers in pregnancies in women with diabetes or gestational

- diabetes. *Diabetic medicine: a journal of the British Diabetic Association*. 2010; 27(11):1264–70. doi: [10.1111/j.1464-5491.2010.03099.x](https://doi.org/10.1111/j.1464-5491.2010.03099.x). PMID: [20950384](https://pubmed.ncbi.nlm.nih.gov/20950384/).
19. Buxton JL, Walters RG, Visvikis-Siest S, Meyre D, Froguel P, Blakemore AI. Childhood obesity is associated with shorter leukocyte telomere length. *The Journal of clinical endocrinology and metabolism*. 2011; 96(5):1500–5. doi: [10.1210/jc.2010-2924](https://doi.org/10.1210/jc.2010-2924). PMID: [21349907](https://pubmed.ncbi.nlm.nih.gov/21349907/); PubMed Central PMCID: PMCPMC3137462.
20. Entringer S, Epel ES, Kumsta R, Lin J, Hellhammer DH, Blackburn EH, et al. Stress exposure in intra-uterine life is associated with shorter telomere length in young adulthood. *Proceedings of the National Academy of Sciences of the United States of America*. 2011; 108(33):E513–8. Epub 2011/08/05. doi: [10.1073/pnas.1107759108](https://doi.org/10.1073/pnas.1107759108). PMID: [21813766](https://pubmed.ncbi.nlm.nih.gov/21813766/); PubMed Central PMCID: PMCPMC3158153.
21. Biron-Shental T, Sukenik-Halevy R, Naboani H, Liberman M, Kats R, Amiel A. Telomeres are shorter in placentas from pregnancies with uncontrolled diabetes. *Placenta*. 2015; 36(2):199–203. doi: [10.1016/j.placenta.2014.11.011](https://doi.org/10.1016/j.placenta.2014.11.011). PMID: [25499309](https://pubmed.ncbi.nlm.nih.gov/25499309/).
22. Makino N, Sasaki M, Maeda T, Mimori K. Telomere biology in cardiovascular disease—role of insulin sensitivity in diabetic hearts. *Experimental and clinical cardiology*. 2010; 15(4):e128–33. Epub 2011/01/26. PMID: [21264070](https://pubmed.ncbi.nlm.nih.gov/21264070/); PubMed Central PMCID: PMCPMC3016072.
23. Broer L, Codd V, Nyholt DR, Deelen J, Mangino M, Willemsen G, et al. Meta-analysis of telomere length in 19,713 subjects reveals high heritability, stronger maternal inheritance and a paternal age effect. *Eur J Hum Genet*. 2013; 21(10):1163–8. doi: [10.1038/ejhg.2012.303](https://doi.org/10.1038/ejhg.2012.303). PMID: [23321625](https://pubmed.ncbi.nlm.nih.gov/23321625/); PubMed Central PMCID: PMCPMC3778341.
24. Njajou OT, Cawthon RM, Damcott CM, Wu SH, Ott S, Garant MJ, et al. Telomere length is paternally inherited and is associated with parental lifespan. *Proceedings of the National Academy of Sciences of the United States of America*. 2007; 104(29):12135–9. doi: [10.1073/pnas.0702703104](https://doi.org/10.1073/pnas.0702703104). PMID: [17623782](https://pubmed.ncbi.nlm.nih.gov/17623782/); PubMed Central PMCID: PMCPMC1924539.
25. De Meyer T, Rietzschel ER, De Buyzere ML, De Bacquer D, Van Criekinge W, De Backer GG, et al. Paternal age at birth is an important determinant of offspring telomere length. *Human molecular genetics*. 2007; 16(24):3097–102. doi: [10.1093/hmg/ddm271](https://doi.org/10.1093/hmg/ddm271). PMID: [17881651](https://pubmed.ncbi.nlm.nih.gov/17881651/).
26. Hashimoto K, Koga M. Indicators of glycemic control in patients with gestational diabetes mellitus and pregnant women with diabetes mellitus. *World J Diabetes*. 2015; 6(8):1045–56. doi: [10.4239/wjd.v6.i8.1045](https://doi.org/10.4239/wjd.v6.i8.1045). PMID: [26240701](https://pubmed.ncbi.nlm.nih.gov/26240701/); PubMed Central PMCID: PMCPMC4515444.
27. Svenson U, Nordfjall K, Baird D, Roger L, Osterman P, Hellenius ML, et al. Blood cell telomere length is a dynamic feature. *PloS one*. 2011; 6(6):e21485. doi: [10.1371/journal.pone.0021485](https://doi.org/10.1371/journal.pone.0021485). PMID: [21720548](https://pubmed.ncbi.nlm.nih.gov/21720548/); PubMed Central PMCID: PMCPMC3123359.
28. Matsui-Hirai H, Hayashi T, Yamamoto S, Ina K, Maeda M, Kotani H, et al. Dose-dependent modulatory effects of insulin on glucose-induced endothelial senescence in vitro and in vivo: a relationship between telomeres and nitric oxide. *The Journal of pharmacology and experimental therapeutics*. 2011; 337(3):591–9. Epub 2011/03/02. doi: [10.1124/jpet.110.177584](https://doi.org/10.1124/jpet.110.177584). PMID: [21357660](https://pubmed.ncbi.nlm.nih.gov/21357660/).
29. Zee RY, Ridker PM, Chasman DI. Genetic variants of 11 telomere-pathway gene loci and the risk of incident type 2 diabetes mellitus: the Women's Genome Health Study. *Atherosclerosis*. 2011; 218(1):144–6. Epub 2011/06/15. doi: [10.1016/j.atherosclerosis.2011.05.013](https://doi.org/10.1016/j.atherosclerosis.2011.05.013). PMID: [21665207](https://pubmed.ncbi.nlm.nih.gov/21665207/); PubMed Central PMCID: PMCPMC3175791.
30. Guo N, Parry EM, Li LS, Kembou F, Lauder N, Hussain MA, et al. Short telomeres compromise beta-cell signaling and survival. *PloS one*. 2011; 6(3):e17858. doi: [10.1371/journal.pone.0017858](https://doi.org/10.1371/journal.pone.0017858). PMID: [21423765](https://pubmed.ncbi.nlm.nih.gov/21423765/); PubMed Central PMCID: PMCPMC3053388.